A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Inclusion Criteria:

1. Histologically diagnosed high-grade serous or endometrioid ovarian cancer (includingprimary peritoneal and fallopian tube cancer)

2. Completion of ≥2 previous platinum-containing regimens

3. Complete response (CR) or partial response (PR) achieved with last platinum-basedchemotherapy regimen as determined by investigator

4. Ability to be randomized ≤8 weeks after last dose of platinum

Exclusion Criteria:

1. Prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor

2. Patients who have received other study drug treatment within 4 weeks prior to thefirst administration(< 5 elimination half-lives of the study drug molecular targetedanti-cancer drugs).

3. Patients with clinical symptoms of cancer ascites, pleural effusion, who need todrainage, or who have undergone ascites drainage within 2 months prior to the firstadministration.